This inventor holds 13 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignees: Janssen Pharmaceuticals, Inc., Biomerieux, Inc., University of Cambridge. Active years: 2003-2021.
Company Filing History:
8 out of 161 
3 out of 645 
2 out of 439 
Years Active: 2003-2021
Title: Trevor Baglin: Innovator in Thrombin-Binding Antibody Molecules
Introduction
Trevor Baglin is a distinguished inventor based in Cambridge, GB. He has made significant contributions to the field of biochemistry, particularly in the development of thrombin-binding antibody molecules. With a total of 13 patents to his name, Baglin's work has the potential to impact medical treatments significantly.
Latest Patents
Among his latest patents is the invention titled "Thrombin-binding antibody molecules and uses thereof." This invention relates to isolated antibodies that recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism, and other conditions mediated by thrombin.
Career Highlights
Trevor Baglin has worked with notable companies in the pharmaceutical industry, including Janssen Pharmaceuticals, Inc. and bioMérieux, Inc. His experience in these organizations has allowed him to develop innovative solutions that address critical health issues.
Collaborations
Some of his notable coworkers include James Andrew Huntington and Jonathan Langdown. Their collaborative efforts have contributed to the advancement of research in the field of thrombin-related therapies.
Conclusion
Trevor Baglin's innovative work in thrombin-binding antibody molecules showcases his commitment to advancing medical science. His contributions have the potential to improve treatment options for patients suffering from thrombotic conditions.